last
year
seen
explos
field
new
pathogen
discov
new
diagnost
test
introduc
new
vaccin
trial
antivir
drug
show
success
human
metapneumoviru
initi
thought
import
rsv
thought
common
rsv
diseas
milder
recent
observ
indic
humpv
usual
sever
part
mix
infect
unusu
adult
though
caus
outbreak
elderli
coronaviru
hit
headlin
form
sar
anoth
exampl
describ
year
earli
tell
import
account
small
proport
previous
undiagnos
respiratori
tract
infect
inform
becom
avail
rhinovirus
commonest
precipit
factor
asthma
also
found
exacerb
copd
increasingli
recognis
signific
caus
pneumonia
includ
immunosuppress
influenza
continu
hit
headlin
south
east
asia
epidem
avian
influenza
hope
set
transmiss
chain
human
point
mutat
influenza
virus
strongli
associ
increas
virul
human
diagnost
front
nucleic
acid
test
becom
predomin
mani
laboratori
expect
stop
cultur
respiratori
virus
within
year
nucleic
acid
test
rapid
significantli
sensit
allow
greater
number
pathogen
detect
either
cultur
direct
fluoresc
full
respiratori
screen
includ
staff
cost
approxim
euro
cidofovir
show
efficaci
adenoviru
infect
immunocompromis
although
reduc
immunosuppress
probabl
efficaci
new
monoclon
antibodi
rsv
place
vaccin
trial
rsv
parainfluenza
despit
geograph
variat
consist
pattern
escherichia
coli
main
host
ctxm
enzym
occur
commun
well
nosocomi
isol
produc
urinari
infect
bacteraemia
prior
ctxm
produc
unrecord
uk
past
month
armrl
receiv
refer
e
coli
isol
ctxm
enzym
uk
lab
repres
fraction
produc
one
trust
alon
infect
due
produc
refer
isol
blactamas
type
belong
one
major
strain
design
four
strain
five
serotyp
mayb
common
ancestor
remain
produc
clonal
divers
produc
gp
patient
mani
elderli
underli
diseas
recent
hospit
contact
multiresist
consist
suscept
carbapenem
nitrofurantoin
fosfomycin
strain
also
suscept
gentamicin
spread
ctxm
enzym
forc
rethink
esbl
detect
method
ceftazidim
resist
previous
advoc
singl
indic
like
esbl
producersi
inconsist
among
ctxm
produc
addit
necessari
test
cefotaxim
altern
isol
may
screen
cefpodoxim
resist
isol
resist
cephalosporin
confirmatori
test
perform
seek
synergi
indic
cephalosporin
clavulan
acid
spread
ctxm
enzym
commun
e
coli
mean
isol
gp
sampl
also
need
screen
method
nosocomi
isol
diagnosi
manag
tubercul
mening
challeng
physician
worldwid
severest
form
infect
mycobacterium
tuberculosi
caus
death
sever
neurolog
deficit
half
affect
despit
treatment
antituberculosi
chemotherapi
diagnost
method
improv
littl
sinc
robert
koch
first
stain
bacilli
treatment
advanc
sinc
introduct
mycobacterium
tuberculosi
antituberculosi
drug
impact
coinfect
human
immunodefici
viru
hiv
although
older
method
diagnosi
treatment
still
import
role
play
meet
challeng
novel
solut
urgent
requir
earli
diagnosi
treatment
greatest
impact
outcom
tubercul
mening
best
diagnost
method
remain
uncertain
role
clinic
diagnost
algorithm
convent
bacteriolog
molecular
techniqu
discuss
impact
hiv
infect
mycobacteri
drug
resist
perform
method
unpublish
data
adjunct
corticosteroid
long
suggest
treatment
tubercul
mening
evid
improv
outcom
difficult
obtain
data
hiv
infect
individu
recent
conduct
doubl
blind
placebo
control
trial
determin
whether
adjunct
dexamathason
improv
outcom
adult
tubercul
mening
without
hiv
infect
result
suggest
dexamethason
improv
surviv
tubercul
mening
prevent
sever
disabl
influenc
hiv
infect
mycobacteri
drug
resist
clinic
present
respons
treatment
outcom
examin
dexamethason
improv
surviv
unclear
data
present
parallel
studi
assess
serial
cerebrospin
fluid
peripher
blood
inflammatori
respons
adult
tubercul
mening
randomis
dexamethason
placebo
conclus
mycobacteri
drug
resist
hiv
infect
set
new
challeng
diagnosi
manag
tubercul
mening
mani
avail
solut
old
prompt
diagnosi
treatment
remain
greatest
influenc
physician
outcom
diseas
still
depend
applic
simpl
wide
avail
clinic
laboratori
techniqu
compel
evid
adjunct
dexamethason
improv
surviv
tubercul
mening
given
adult
regardless
diseas
sever
best
treatment
hiv
associ
drug
resist
tubercul
mening
remain
uncertain
studi
assess
impact
optim
time
secondlin
antituberculosi
drug
antiretrovir
treatment
urgent
requir
index
patient
receiv
haemodialysi
rph
outpati
isol
strict
contact
precaut
screen
patient
dialysi
unit
nephrolog
ward
icu
approxim
weekli
next
month
reveal
carrier
pulsedfield
gel
electrophoresi
plasmid
analysi
isol
demonstr
singlestrain
despit
isol
carrier
vref
spread
rapidli
late
septemb
epidem
strain
spread
ward
one
outpati
unit
satellit
dialysi
patient
infect
colon
hospit
vre
execut
group
includ
chief
execut
director
clinic
servic
nurs
form
manag
outbreak
directli
daili
meet
control
handicap
slow
convent
laboratori
method
took
day
identifi
vre
allow
nosocomi
transmiss
occur
carrier
identifi
laboratori
procedur
make
rapid
provision
identif
vre
develop
rectal
swab
incub
select
enrich
broth
least
h
multiplex
pcr
vana
vanb
gene
perform
directli
posit
broth
cultur
use
novel
hybrid
probe
develop
improv
specif
sensit
assay
averag
rectal
swab
collect
separ
day
need
detect
vref
carrier
epidemiolog
link
outbreak
enhanc
infect
control
practic
use
erad
singlestrain
outbreak
cohort
posit
ward
contact
patient
separ
ward
dedic
nurs
staff
cohort
inpati
ward
contact
known
exposur
screen
period
identifi
total
reservoir
vref
carriag
previous
unknown
carrier
found
establish
dedic
vre
ward
clean
servic
durat
outbreak
environment
cultur
establish
termin
clean
adequ
electron
flag
medic
record
ward
contact
period
julydecemb
patient
carrier
detect
screen
hospit
electron
flag
ward
contact
enabl
screen
least
time
discharg
followedup
screen
septemb
april
total
ward
contact
screen
discharg
hospit
found
carri
vref
electron
label
activ
followup
ward
contact
result
signific
number
carrier
detect
otherwis
pose
risk
initi
outbreak
hospit
readmit
ongo
control
facilit
target
activ
surveil
cultur
admiss
highrisk
unit
icu
burn
nephrolog
haematolog
bone
marrow
transplant
unit
transfer
icu
monthli
screen
patient
regularli
attend
display
unit
opportunist
laboratori
screen
inpati
faecal
specimen
submit
clostridium
difficil
cultur
listeria
monocytogen
foodborn
pathogen
respons
listeriosi
human
infect
overal
mortal
rate
character
sever
gastroenter
fetoplacent
central
nervou
system
infect
microorgan
abil
cross
three
tight
barrier
human
intestin
bloodbrain
fetoplacent
barrier
infect
enter
surviv
multipli
phagocyt
nonphagocyt
cell
also
spread
directli
cell
cell
featur
consid
central
listeriosi
pathophysiolog
infecti
process
extens
studi
tissuecultur
cell
seri
event
occur
initi
bacteri
cell
contact
includ
format
phagocyt
vacuol
lysi
vacuol
within
min
intracytosol
replic
actinbas
intracellular
movement
celltocel
spread
l
monocytogen
entri
human
epitheli
cell
trigger
interact
bacteri
surfac
protein
call
internalin
host
receptor
ecadherin
transmembrarn
protein
critic
format
mainten
adher
junction
epitheli
tissu
internalinecadherin
interact
speciesspecif
mous
ecadherin
contrast
human
ecadherin
receptor
internalin
speciesspecif
reli
natur
ecadherin
amino
acid
prolin
human
glutam
acid
mice
replac
glutam
acid
prolin
lead
gain
function
establish
critic
role
residu
ecadherininternalin
interact
transgen
mice
express
human
ecadherin
contrast
nontransgen
mice
highli
permiss
oral
acquir
listeriosi
demonstr
essenti
role
internalin
l
monocytogen
abil
cross
intestin
barrier
epidemiolog
survey
indic
l
monocytogen
strain
isol
pregnancyrel
case
express
fulllength
function
internalin
compar
strain
isol
food
product
result
favor
critic
role
internalin
target
cross
human
maternofet
barrier
examin
iminumohistochem
label
placent
amniot
tissu
sampl
obtain
women
pregnancyassoci
listeriosi
rais
possibl
l
monocytogen
cross
maternofet
barrier
villou
syncytiotrophoblast
investig
cellular
pattern
express
receptor
ecadherin
maternofet
interfac
demonstr
ecadherin
express
basal
apic
plasma
membran
syncytiotrophoblast
quantit
assay
cellular
invas
trophoblast
cell
line
primari
trophoblast
cultur
placent
villou
explant
demonstr
bacteri
entri
syncytiotrophoblast
occur
via
apic
membran
internalinecadherin
depend
thermal
human
placent
villou
explant
bacteri
invas
syncytiotrophoblast
barrier
underli
villou
tissu
subsequ
replic
produc
histopatholog
lesion
mimic
seen
placenta
women
listeriosi
thu
internalinecadherin
interact
play
key
role
cross
intestin
barrier
also
exploit
l
monocytogen
target
cross
human
placent
barrier
current
studi
focu
molecular
mechan
l
monocytogen
cross
bloodbrain
barrier
walsh
depart
patholog
microbiolog
univers
bristol
bristol
uk
millennia
bacteria
adjust
extern
stimuli
adjust
employ
sever
mechan
protect
cell
harm
toxin
ultim
elud
certain
death
mechan
express
either
constitut
cell
requir
itterm
induc
cell
procur
either
mechan
either
rearrang
dna
term
intrins
sequest
foreign
dna
term
acquir
latter
perceiv
clinic
threat
organ
usual
express
mechan
constitut
predict
organ
new
mechan
appear
problemat
centuri
resist
must
seen
global
problem
increas
intern
mobil
human
popul
increas
resist
commun
bacteria
possess
remark
plastic
genet
element
contribut
current
antibiot
resist
rate
seen
uk
european
hospit
bacteri
pathogen
acquir
sever
mechan
acquir
new
dna
conjug
transform
transduct
concurr
bacteria
also
acquir
new
antibiot
resist
gene
highli
mobil
gene
cassett
embed
ambulatori
genet
element
call
integron
integron
embed
transposon
associ
mobil
dna
region
call
common
region
element
recent
postul
pathogen
island
also
contribut
gene
transfer
use
gramneg
quinolon
resist
extendedspectrum
blactamas
exampl
aforement
mechan
gene
transfer
explor
contribut
clinic
antibiot
resist
g
smith
region
centr
mycobacteriolog
west
midland
public
health
laboratori
health
protect
agenc
birmingham
heartland
hospit
bordesley
green
east
uk
recent
publish
action
plan
chief
medic
offic
stop
tuberculosi
england
set
step
govern
health
servic
local
commun
need
take
revers
rise
tb
plan
includ
develop
implement
protocol
public
health
use
laboratori
techniqu
dna
fingerprint
mycobacterium
tuberculosi
isol
establish
central
databas
link
fingerprint
epidemiolog
data
central
system
enabl
earli
defect
outbreak
rapidli
elimin
case
outbreak
cohort
facilit
appropri
focus
contact
trace
effort
thu
limit
spread
infect
applic
molecular
microbiolog
method
improv
understand
popul
structur
dynam
spread
number
infecti
agent
method
also
allow
genet
comparison
strain
facilit
identif
genet
basi
medic
relev
microbiolog
trait
tuberculosi
exampl
bacteri
speci
sever
wellstandard
power
method
epidemiolog
character
develop
countri
haw
carri
longitudin
epidemiolog
surveil
allow
databas
exchang
compar
techniqu
use
wide
restrict
fragment
length
polymorph
rflp
spoligotyp
use
success
investig
strain
patient
epidemiolog
lift
provid
inform
popul
genet
tuberculosi
local
global
neither
techniqu
ideal
rapid
high
volum
discriminatori
analysi
recent
isol
strain
tuberculosi
allow
direct
applic
type
inform
inform
investig
contact
trace
new
case
characterist
requir
allow
unsuspect
cluster
identifi
extent
cluster
map
prospect
improv
diseas
control
prevent
rapid
type
made
avail
case
manag
treatment
also
improv
opportun
recognis
microbiolog
clinic
trait
associ
particular
type
profil
health
protect
agenc
develop
nation
type
strategi
tb
select
method
variabl
number
tandem
repeat
type
use
exact
tandem
repeat
etr
loci
mycobacteri
interspers
repetit
unit
miru
loci
produc
digit
profil
strain
prospect
type
servic
implement
across
midland
juli
type
result
report
directli
tb
nurs
health
protect
team
local
laboratori
type
inform
focus
contact
trace
assist
infect
control
manag
difficult
patient
tb
team
swiftli
realis
benefit
type
strategi
abl
limit
cancel
extens
contact
trace
exercis
type
distinguish
appar
cluster
strain
type
servic
roll
region
centr
mycobacteriolog
rest
england
nation
databas
underdevelop
anticip
wider
avail
servic
enhanc
contribut
tb
prevent
control
vaccin
prove
highli
effect
across
age
group
also
induc
herd
immun
protect
popul
larg
effort
develop
vaccin
comprehens
meningococci
concentr
sub
capsular
antigen
particularli
porin
protein
protein
howev
highli
variabl
sub
capsular
antigen
tend
specif
particular
strain
produc
howev
molecular
epidemiolog
studi
begin
reveal
high
degre
structur
antigen
variabl
structur
provid
clue
possibl
way
forward
develop
comprehens
meningococc
vaccin
outbreak
investig
import
challeng
compon
public
health
serv
identifi
sourc
mean
spread
diseas
action
taken
promptli
prevent
addit
case
even
outbreak
thorough
investig
provid
inform
help
prevent
futur
outbreak
varieti
circumst
pose
difficulti
outbreak
investig
diseas
eas
diagnosi
treatment
sever
symptom
degre
infect
other
set
infect
may
difficult
investig
control
wide
spread
remot
area
infect
close
commun
like
hospit
nurs
home
cruis
ship
militari
facil
prison
pose
specif
problem
recent
prospect
bioterror
ad
new
dimens
investig
unusu
incid
difficult
incid
face
vest
econom
polit
interest
occur
unstabl
polit
context
war
humanitarian
crisi
could
characteris
epidemiologist
nightmar
new
diseas
whose
aetiolog
mode
transmiss
unknown
substanti
fatal
rate
diagnost
test
treatment
vaccin
alreadi
spread
rapidli
popul
gener
public
panic
media
interest
polit
repercuss
littl
bit
like
sar
fact
respons
alway
follow
basic
principl
good
outbreak
investig
first
stage
verifi
fact
confirm
exist
outbreak
develop
case
definit
second
stage
gather
much
inform
possibl
incid
includ
search
undiagnos
case
interview
case
analys
data
time
place
person
well
incorpor
inform
obtain
microbiolog
environment
investig
import
clear
purpos
investig
focu
gener
hypothes
caus
outbreak
keep
open
mind
earli
stage
third
stage
test
hypothes
carri
cohort
casecontrol
studi
seek
draw
firm
conclus
inform
gather
take
action
accordingli
stage
import
keep
log
event
key
decis
coordin
respons
incid
team
ensur
good
commun
colleagu
public
press
other
implement
control
measur
promptli
possibl
final
report
written
crystallis
find
investig
make
appropri
recommend
highlight
lesson
learn
link
visibl
cleanli
healthcar
acquir
infect
firmli
establish
polit
mind
press
public
although
scientif
evid
contenti
eg
matron
charter
action
plan
cleaner
hospit
extent
couldshould
infect
control
practition
other
set
standard
environment
cleanli
recolonis
larg
intestin
normal
flora
attract
therapeut
intervent
treatment
clostridium
difficil
associ
diarrhoea
cdad
break
cycl
recurr
antibiot
administr
recent
use
donor
stool
administ
via
nasogastr
tube
describ
treatment
recurr
cdad
describ
experi
use
techniqu
six
patient
recurr
cdad
patient
present
brownle
centr
year
period
august
recurr
cdad
offer
treatment
faecal
transplant
recurr
cdad
defin
recurr
diarrhoea
presenc
c
difficil
toxin
assay
posit
assum
initi
resolut
symptom
follow
appropri
cours
anti
clostridi
treatment
six
patient
stool
transplant
faec
donat
screen
rel
six
patient
treat
three
cure
cdad
follow
week
one
patient
remain
symptom
free
await
stool
toxin
assay
month
follow
one
patient
remain
c
difficil
toxin
posit
continu
diarrhoea
follow
transplant
patient
howev
respond
cours
metronidazol
remain
symptom
free
c
difficil
toxin
neg
month
follow
final
patient
initi
respond
stool
transplant
diarrhoea
toxin
neg
howev
episod
cdad
subsequ
treat
cours
broad
spectrum
antibiot
case
two
patient
rel
initi
screen
found
posit
c
difficil
toxin
donor
identifi
stool
transplant
effect
therapi
recurr
coad
inexpens
experi
associ
advers
effect
patient
accept
treatment
option
univers
high
despit
obviou
aesthet
problem
screen
stool
donor
time
consum
part
treatment
identif
asymptomat
rel
stool
carriag
c
difficil
recognis
find
underlin
need
appropri
screen
potenti
stool
donor
result
type
clinic
isol
show
indistinguish
differ
isol
obtain
hospit
observ
surgic
practic
reveal
noth
untoward
appear
signific
differ
mode
oper
differ
surgic
team
environment
screen
yield
sever
enterobact
isol
prove
differ
clinic
isol
except
one
isol
cardiac
bypass
cool
water
howev
water
contain
seal
system
machin
use
surgic
team
case
expos
particular
bypass
machin
question
reveal
one
signific
differ
differ
surgic
teamsth
team
infect
patient
use
semifrozen
steril
hartmann
solut
achiev
cardioplegia
iceslush
instil
directli
chest
caviti
surgeri
freezer
use
swab
swab
includ
swab
outsid
hartmann
bag
yield
enterobact
cloaca
indistinguish
clinic
isol
conclus
plausibl
explan
freezer
recent
contamin
enterobact
bacteria
contamin
iceslush
solut
decant
thu
infect
patient
case
sinc
freezer
replac
rigor
clean
schedul
institut
step
taken
reduc
possibl
carryov
contamin
organ
streptococcu
pneumonia
surfac
protein
pspa
cytotoxin
pneumolysin
pli
may
affect
virul
prevent
complement
activ
studi
interact
protein
complement
system
use
mice
specif
defici
complement
compon
mutant
strain
bacteria
defici
pspa
andor
pli
deposit
pneumonia
strain
investig
flow
cytometri
compar
wildtyp
strain
deposit
pli
strain
increas
serum
wild
type
wt
mice
kk
serum
indic
pli
prevent
classic
pathway
activ
contrast
deposit
increas
pspa
k
mutant
strain
kk
serum
suggest
pspa
interfer
altern
pathway
loss
pspa
pli
strongli
synergist
larg
increas
deposit
pspa
k
pli
k
mutant
strain
wt
serum
also
analys
use
mix
infect
wildtyp
complement
defici
mice
whether
pspa
pli
prevent
complement
activ
vivo
pspa
k
pli
k
strain
attenu
virul
compar
wildtyp
strain
wt
mice
pspa
k
strain
greater
degre
pli
k
strain
mice
defici
complement
activ
kk
rel
virul
pspa
k
pli
k
strain
improv
ci
respect
demonstr
loss
virul
mutant
strain
least
partial
depend
complement
activ
compar
pli
k
strain
virul
doubl
pspa
k
pli
k
mutant
strain
wt
mice
dramat
reduc
ci
restor
kk
mice
ci
confirm
synergist
protect
effect
pli
pspa
complement
activ
vivo
site
time
complementmedi
immun
pneumonia
analys
use
mix
infect
compar
pspa
k
pli
k
strain
pli
k
strain
wt
kk
mice
although
role
complementdepend
immun
earli
time
point
within
lung
major
effect
complement
prevent
spread
pneumonia
lung
blood
prevent
inhibit
complementdepend
immun
pneumonia
primari
bacteri
pathogen
could
potenti
novel
therapi
patient
septicaemia
maxim
cation
transport
occur
ph
consist
proton
gradient
base
energet
propos
nramp
orthologu
mn
transport
diminish
presenc
mm
na
c
compat
na
c
slippag
mechan
propos
saccharomyc
cerevisia
nramp
orthologu
conclus
cramp
first
nramp
orthologu
fungal
pathogen
function
characteris
cramp
resembl
fungal
orthologu
respect
predict
membran
topolog
substrat
specif
ph
depend
differ
term
appar
affin
mn
insensit
zn
insight
afford
find
allow
formul
new
hypothes
regard
role
metal
ion
pathophysiolog
cryptococcosi
devast
system
effect
bacteri
superantigen
sag
may
explain
power
proinflammatori
synergi
lipopolysaccharid
lp
howev
mechan
underli
phenomenon
remain
unclear
never
investig
human
specif
known
link
saginduc
immun
effect
patternrecognit
lp
tolllik
receptor
aim
investig
whether
sag
affect
express
lp
receptor
monocyt
determin
phenotyp
sagexpos
mononuclear
cell
regard
lp
respons
determin
whether
cell
signal
mhc
class
ii
signal
play
role
sagmedi
interact
lp
recognit
pathway
method
express
primari
monocyt
determin
flow
cytometri
real
time
pcr
tnf
produc
mononuclear
cell
determin
elisa
role
cell
investig
cell
separ
techniqu
use
sag
construct
target
mutat
mhc
class
ii
cell
receptor
bind
domain
result
staphylococc
streptococc
sag
induc
rapid
transcript
increas
membran
express
primari
human
monocyt
ligat
mhc
class
ii
sag
sole
respons
monocyt
upregul
induc
product
streptococcu
pyogen
parallel
enhanc
express
prime
purifi
monocyt
mix
peripher
blood
monounuclear
cell
sag
significantli
enhanc
induct
proinflammatori
cytokin
known
ligand
sag
construct
contain
target
mutat
use
demonstr
requir
mhc
class
ii
ligat
upregul
enhanc
respons
endotoxin
contrast
result
anim
model
sagendotoxin
interact
depend
cell
receptor
ligat
exotoxin
interferon
gamma
product
summari
patternrecognit
bacteri
sag
mhc
class
ii
receptor
may
exacerb
proinflammatori
respons
monocyt
gramneg
infect
endotoxin
upragul
similarli
flow
cytometri
reveal
reduct
alveolar
macrophag
apoptosi
incid
bacteraemia
h
greater
ino
defici
mice
wild
type
ino
kk
vs
similar
two
strain
h
ino
kk
vs
clearanc
bacteria
similar
two
strain
time
point
significantli
greater
number
pmn
balf
h
infect
ino
kk
vs
p
differ
pmn
balf
mock
infect
mice
two
strain
day
differ
surviv
howev
surviv
h
ino
kk
mice
conclus
ino
defici
associ
reduct
apoptosi
earlier
bacteraemia
earlier
death
greater
recruit
pmn
ino
kk
mice
result
similar
bacteri
clearanc
lung
signific
differ
long
term
surviv
two
strain
expens
greater
lung
inflamm
investig
ccr
express
monocyt
rsvinfect
infant
healthi
control
patient
infant
admit
intensivecar
age
day
male
confirm
rsv
infect
admit
studi
infant
age
day
male
undergo
elect
surgeri
recruit
uninfect
control
questionnair
includ
detail
rsv
risk
factor
cours
durat
diseas
complet
patient
method
ml
blood
taken
patient
monocyt
isol
tini
amount
fresh
blood
use
novel
densiti
gradient
adher
method
half
cell
infect
rsv
half
treat
neg
control
uvlight
inactiv
rsv
lnrsv
level
determin
use
fac
analysi
calcium
flux
measur
ratio
assay
statist
test
wilcoxin
mannwhitneyu
spearmansrho
perform
use
spss
softwar
result
imonocyt
rsvpatient
stimul
ex
vivo
viru
significantli
higher
level
rsv
stimul
monocyt
control
patient
p
monocyt
control
rsvpatient
upregul
respons
rsv
compar
uvrsv
neg
control
p
p
increas
greater
monocyt
rsvpatient
therefor
monocyt
rsvinfect
babi
appear
prime
upregul
respons
rsv
express
coregul
express
level
correl
r
p
calcium
flux
measur
show
upregul
receptor
function
fold
increas
correl
significantli
key
marker
diseas
sever
durat
hospit
admiss
durat
intens
care
stay
conclus
data
show
rsv
caus
function
increas
chemokin
receptor
express
upregul
link
diseas
sever
infant
patient
studi
sexual
contact
regular
casual
contact
total
contact
could
trace
screen
remain
could
identifi
partner
notif
despit
intens
track
attempt
conclus
studi
illustr
lack
patient
complianc
posttreat
serolog
follow
simplif
follow
may
improv
patient
complianc
posttreat
serolog
low
success
rate
partner
notif
mainli
due
anonym
sex
may
drive
syphili
epidem
attempt
improv
nation
sought
introduct
immun
restor
diseas
ird
collect
inflammatori
diseas
seen
hiv
patient
hiv
viraemia
suppress
highli
activ
antiretrovir
therapi
haart
ird
probabl
reflect
dysregul
immun
respons
proexist
infect
opportunist
pathogen
postul
patient
profoundli
suppos
lymphocyt
count
suscept
ird
method
royal
perth
hospit
cohort
approxim
hivposit
patient
retrospect
case
note
studi
perform
examin
patient
count
cellsmm
less
commenc
haart
total
pt
june
june
identifi
patient
exclud
less
month
therapi
complet
lost
follow
poor
complianceadher
haart
identifi
signific
reduct
hiv
viral
load
log
baselin
viral
load
follow
month
treatment
total
patient
fulfil
criteria
commenc
haart
studi
period
one
episod
could
studi
patient
total
episod
analys
patient
clinic
ward
attend
examin
occurr
possibl
case
ird
note
result
patient
mean
age
commenc
haart
year
yr
sex
male
femal
ethnic
caucasian
se
asian
african
indigen
australian
haart
regim
use
proteas
inhibitor
base
nonnucleosid
revers
transcriptas
inhibitor
base
mean
baselin
count
cellsmm
mean
baselin
hiv
viral
load
copiesml
total
case
ird
diagnos
atyp
mycobacteri
infect
kaposi
sarcoma
vzv
cerebr
taxoplasmosi
tuberculosi
cylomegaloviru
anterior
uveiti
cryptococcosi
molluscum
contagiosum
progress
multifoc
leucoencephalopathi
dissemin
hsv
parvoviru
enceph
possibl
case
also
occur
elev
transaminas
chronic
hepat
patient
hepat
c
hepat
b
conclus
patient
count
cellsmm
may
risk
develop
ird
compar
data
studi
comment
manag
individu
case
object
evalu
effector
function
tuberculosi
purifi
protein
deriv
ppd
specif
c
cell
c
subject
long
term
highlyact
antiretrovir
therapi
haart
method
ppdspecif
c
cell
quantifi
ifng
elispot
crosssect
studi
c
subject
receiv
haart
month
count
cellsml
agematch
low
risk
control
subject
bcgvaccin
cytokin
profil
respond
cell
analys
intracellular
stain
result
frequenc
ifngsecret
ppdspecif
c
cell
significantli
lower
c
subject
compar
control
median
sfumillion
pbmc
respect
p
irrespect
nadir
durat
haart
contrast
high
frequenc
cmvspecif
c
cell
ifngsecret
capac
detect
cmvseroposit
c
subject
evid
switch
respons
frequenc
ppdspecif
c
cell
secret
ifng
similar
among
c
subject
ppdspecif
prolif
respons
demonstr
subset
c
subject
exagen
could
restor
ifng
secret
respons
ppd
stimul
indic
ppdspecif
c
cell
present
individu
conclus
taken
togeth
data
indic
select
loss
function
ppdspecif
c
cell
c
subject
due
defect
ifng
axi
appear
recov
long
term
haart
ifng
key
mediat
immun
tuberculosi
find
implic
risk
activ
tuberculosi
tb
haarttreat
subject
particularli
area
high
tb
preval
haart
yet
implement
larg
scale
method
order
plan
progress
tuberculosi
control
plan
within
hospit
set
manag
suspect
actual
case
tuberculosi
key
staff
includ
modern
matron
ask
produc
patient
care
pathway
ward
depart
ask
includ
inform
role
respons
key
personnel
respond
also
ask
would
inform
provid
inform
patient
accommod
provis
advic
patient
detail
person
protect
equip
result
wide
rang
respons
receiv
drawn
varieti
way
either
individu
act
isol
part
group
exercis
comprehens
pathway
care
receiv
form
care
elderli
director
includ
action
taken
commun
well
within
hospit
set
reflect
way
healthcar
deliveri
organis
one
respond
indic
need
protocol
screen
well
women
despit
fact
multidrug
resist
tuberculosi
identifi
patient
visit
depart
conclus
work
need
done
improv
staff
knowledg
regard
risk
assess
well
manag
suspectedknown
case
tuberculosi
particularli
regard
use
person
protect
equip
methicillinresist
staphylococcu
aureu
mrsa
major
human
pathogen
commun
healthcar
set
caus
infect
rang
boil
cellul
lifethreaten
diseas
osteomyel
bacteraemia
epidem
spread
mrsa
due
mainli
dissemin
strain
enhanc
capabl
dispers
transmiss
effect
control
measur
depend
detail
knowledg
strain
characterist
potenti
inform
epidemiolog
studi
impact
infect
control
strategi
last
two
decad
uk
epidem
methicillinresist
aureu
emrsa
type
defin
phage
type
although
phage
type
recent
pfge
wide
use
studi
epidemiolog
mrsa
interlaboratori
reproduc
limit
hamper
strain
comparison
centr
countri
advent
newer
portabl
molecular
type
method
offer
promis
overcom
limit
enhanc
characteris
refer
strain
exploit
rang
molecular
techniqu
includ
dna
sequenc
pcrbase
method
multi
locu
sequenc
type
mlst
protein
gene
spa
sequenc
type
toxin
profit
accessori
gene
regul
agr
allel
determin
staphylococc
cassett
chromosom
mec
sccmec
type
data
show
variabl
discriminatori
power
emrsa
strain
term
sequenc
st
spa
type
agr
group
scc
mec
type
provid
valuabl
insight
phylogenet
evolutionari
relationship
exampl
st
spa
type
agr
sccmec
iii
also
encod
singl
enterotoxin
sea
result
show
emrsa
deriv
similar
genet
background
howev
success
uk
epidem
strain
emrsa
mlst
spa
type
agr
group
sccmec
type
differ
show
distinct
genet
lineag
suggest
factor
import
pathogen
epidem
discriminatori
power
afford
techniqu
augment
outbreak
investig
improv
abil
map
emerg
spread
resist
andor
virul
clone
commun
healthcar
set
introduct
cranberri
juic
given
elderli
hospitalis
patient
belief
prevent
treat
urinari
tract
infect
uti
though
good
evid
effect
decreas
symptomat
uti
younger
women
whether
effect
elderli
women
men
unknown
mechan
effect
cranberri
mediat
thought
due
presenc
proanthocyanidin
exhibit
antiadhes
activ
sensit
resist
strain
pfimbriat
e
coli
prevent
adher
uroepitheli
cell
line
wall
bladder
cranberri
juic
attract
therapi
cheap
natur
lead
antibiot
resist
studi
sought
examin
potenti
prevent
symptomat
uti
elderli
hospitalis
patient
risk
advers
effect
multipl
cours
antibiot
abstract
randomis
placebo
control
doubl
blind
trial
patient
age
admit
medicin
elderli
assess
rehabilit
unit
taysid
particip
given
either
dml
cranberri
juic
placebo
twice
daili
juic
prescrib
ward
drug
kardex
primari
outcom
time
onset
first
uti
secondari
outcom
complianc
drink
juic
antibiot
prescript
bacteria
isol
uti
high
adher
fate
drink
juic
around
achiev
total
subject
develop
uti
placebo
group
cranberri
juic
group
significantli
fewer
escherichia
coli
infect
cranberri
group
larg
randomis
clinic
trial
cranberri
juic
ingest
includ
male
femal
symptomat
infect
rate
lower
anticip
studi
underpow
thu
inconclus
larger
trial
need
provid
definit
result
meanwhil
role
cranberri
juic
prevent
uti
elderli
hospit
patient
remain
unproven
june
ga
isol
clinic
site
three
differ
patient
postpartum
mother
case
babi
case
one
babi
case
b
two
women
case
c
return
unit
seriou
infect
requir
admiss
intens
care
unit
matern
unit
close
investig
could
undertaken
appropri
infect
control
measur
implement
prevent
case
outbreak
group
establish
includ
intern
extern
repres
regular
meet
group
held
cours
outbreak
unit
close
new
admiss
except
women
present
advanc
labour
obstetr
emerg
prioriti
reopen
unit
soon
possibl
reliev
pressur
referr
neighbour
unit
commun
gener
practition
catchment
area
seek
cooper
identif
case
new
case
identifi
commun
three
hundr
staff
screen
within
day
period
posit
isol
found
deep
clean
environ
patient
share
equip
coordin
infect
control
team
item
equip
potenti
reservoir
infect
systemat
audit
item
equip
includ
sever
cot
mattress
deliveri
bed
mattress
condemn
replac
type
isol
case
case
case
b
found
type
refer
laboratori
evid
suggest
transmiss
case
case
case
b
case
c
assess
deliveri
suit
within
h
deliveri
case
case
b
case
c
microbiolog
neg
strong
circumstanti
clinic
evid
cross
infect
occur
case
exclud
outbreak
follow
recommend
made
outbreak
group
lookback
exercis
patient
share
equip
subject
plan
programm
audit
replac
undertak
review
local
polic
pertin
infect
control
clinic
staff
attend
mandatori
infect
control
train
review
domest
hour
input
unit
prevent
control
hospit
acquir
infect
given
high
prioriti
increas
attent
focuss
mainten
clean
hospit
environ
ward
curtain
surround
hospit
bed
give
patient
privaci
like
surfac
ward
environ
expos
contamin
hospit
microbi
pathogen
deriv
patient
staff
consequ
curtain
may
play
role
spread
nosocomi
infect
import
probabl
overlook
past
taunton
somerset
nh
trust
curtain
launder
site
often
short
suppli
sudden
increas
demand
overcom
limit
rapid
curtain
decontamin
situ
use
robbi
steam
cleaner
introduc
studi
undertaken
littl
inform
avail
effect
steam
clean
curtain
area
curtain
sampl
use
casella
slit
sampler
accord
standard
protocol
area
chosen
identifi
like
contamin
patient
staff
bacteri
load
launder
curtain
linen
room
curtain
clinic
area
steam
clean
investig
total
coloni
count
cfu
record
arid
data
set
analys
statist
use
minitab
steam
clean
curtain
clinic
area
result
signific
reduct
coloni
count
p
steam
clean
bacteri
load
curtain
clinic
area
compar
store
clean
launder
curtain
qualit
studi
carri
identifi
variou
speci
organ
present
launder
curtain
curtain
clinic
area
includ
surround
bed
patient
known
mrsa
posit
isoelectr
focus
confirm
presenc
induc
blactamas
high
pl
consist
presenc
ampc
blactamas
molecular
type
method
reveal
two
clone
present
first
caus
invas
clinic
infect
babi
afterward
replac
second
noninvas
clone
affect
babi
phenotyp
two
strain
also
differ
prodigiosin
product
first
one
nonpig
wherea
second
one
display
pinkr
pigment
environment
isol
clinic
isol
ward
genet
distinct
although
marcescen
continu
isol
occasion
end
outbreak
signal
replac
origin
strain
sporad
strain
molecular
type
pattern
conclus
clear
differ
pathogen
two
outbreak
clone
molecular
type
method
use
epidemiolog
tool
emphas
differ
two
outbreak
strain
rapdpcr
although
rel
easi
perform
limit
reproduc
wherea
pfge
discriminatori
arid
reproduc
forthcom
month
peopl
travel
uk
sar
zone
potenti
reemerg
repetit
warn
concern
next
flu
pandem
opportun
prepar
contain
infect
earli
possibl
prevent
nosocomi
amplif
sar
postoutbreak
period
patient
febril
respiratori
ill
refer
north
manchest
gener
hospit
evalu
possibl
sarscov
infect
patient
recent
return
uk
mainland
china
ill
start
prior
departur
china
cours
patient
admiss
sever
factor
emerg
practic
aspect
patient
care
believ
need
detail
step
step
guidanc
clinician
regard
day
day
manag
case
result
experi
patient
highlight
sever
issu
optim
prepar
potenti
case
sarscov
avian
influenza
infect
may
includ
follow
hospit
plan
develop
deal
case
multi
disciplinari
approach
crucial
plan
provid
detail
requir
variou
parti
assess
compon
planpolici
gener
regard
infecti
diseas
build
practic
prepared
exampl
develop
preprepar
kit
includ
may
requir
assess
lamin
aid
memoir
wall
isol
room
give
clear
step
step
guidanc
person
protect
equip
ppe
usag
etc
train
staff
regular
updat
includ
basic
principl
provid
safe
case
manag
involv
risk
assess
adapt
normal
clinic
practic
protocol
regard
use
antivir
data
collect
optimis
day
day
infect
control
practic
commun
plan
develop
includ
contact
conclus
think
hospit
prepared
paramount
gener
compon
utilis
infecti
diseas
clinic
applic
haccp
c
griffith
p
obe
r
cooper
school
appli
scienc
uwic
cardiff
uk
background
object
healthcar
associ
infect
hai
continu
attract
media
consum
attent
impact
upon
healthcar
deliveri
caus
morbid
modal
win
way
nh
action
plan
identifi
seven
action
area
area
one
recommend
use
hazard
analysi
critic
control
point
haccp
although
littl
guidanc
applic
provid
studi
appli
approach
strategi
base
upon
haccp
relev
prerequisit
programm
prp
decontamin
endoscop
method
observ
practic
combin
examin
document
use
endoscopi
clinic
undertaken
procedur
use
compar
haccp
principl
logic
sequenc
outlin
codex
alimentariu
committe
real
time
monitor
defin
codex
undertaken
clean
prior
disinfect
use
atp
bioluminesc
provid
measur
residu
organ
debri
result
endoscop
reprocess
conduct
accord
british
societi
gastroenterolog
guidelin
comparison
use
practic
haccp
principl
indic
variabl
unit
neither
unit
implement
haccp
step
monitor
indic
clean
essenti
step
prior
decontamin
often
adequ
perform
biopsi
suction
channel
endoscop
process
unit
found
contain
organ
matter
water
use
decontamin
good
microbiolog
qualiti
although
endoscop
tip
found
contamin
environment
surfac
like
contact
clean
endoscop
conclus
haccp
prp
approach
appli
healthcar
environ
could
help
reduc
healthcar
acquir
infect
provid
risk
base
manag
framework
import
contribut
infect
control
programm
reduc
patient
morbid
modal
treatment
cost
incur
hospit
wall
recogn
also
acknowledg
noncompli
standard
precaut
may
relat
lack
knowledg
amongst
healthcar
worker
regard
potenti
risk
infect
transmiss
patient
infect
control
guidelin
cork
univers
hospit
updat
juli
decid
follow
introduct
guidelin
ascertain
level
knowledg
nurs
medic
staff
regard
fundament
aspect
infect
control
practic
prior
introduct
guidelin
infect
control
teach
occur
inform
basi
warddepart
sporad
natur
due
staff
shortag
method
design
short
anonym
crosssect
questionnair
consist
question
base
core
element
first
three
chapter
infect
control
guidelin
result
major
respond
femal
member
nurs
staff
need
place
patient
singl
room
order
adher
contact
droplet
airborn
precaut
underestim
surgic
wound
infect
urinari
tract
infect
commonli
identifi
exampl
hospitalacquir
infect
vancomycin
recogn
twice
often
linezolid
possibl
choic
antibiot
treatment
patient
seriou
mrsa
infect
greater
awar
risk
transmiss
hepat
c
hiv
hepat
b
case
needlestick
injuri
infect
patient
healthcar
worker
conclus
studi
reveal
lack
knowledg
amongst
nurs
doctor
key
area
infect
control
may
use
guid
teach
session
medic
nurs
staff
reinforc
principl
infect
control
optimis
practic
hospit
result
record
target
urin
sampl
sent
cultur
patient
target
sampl
sent
grew
mix
nonsignific
number
organ
msu
result
record
medic
note
patient
choic
empir
therapi
compar
pre
guidelin
audit
prescrib
trimethroprim
fell
nitrofurantoin
increas
patient
complic
uti
prescrib
nitrofurantoin
patient
empir
therapi
modifi
durat
therapi
patient
uncompl
uti
receiv
day
therapi
target
day
patient
complic
uti
treat
fewer
day
target
day
intend
durat
treatment
document
patient
conclus
introduct
guidelin
associ
fall
prescript
trimethoprim
whilst
nitrofurantoin
increas
nitrofurantoin
often
use
inappropri
patient
complic
uti
durat
therapi
often
consist
guidelin
document
result
intend
treatment
durat
poor
particip
method
result
orthopaed
staff
hospit
ask
particip
subject
group
ask
clean
hand
use
ml
one
applic
suggest
manufactur
alcohol
gel
contain
clear
fluoresc
substanc
uv
light
use
identifi
area
miss
miss
area
record
onto
proforma
assessor
subject
shown
area
miss
retest
way
day
later
view
poster
show
six
recommend
stage
hand
wash
subject
group
ask
clean
hand
two
applic
ml
gel
initi
assess
ident
group
retest
age
year
sex
match
subject
group
comparison
pair
match
job
descript
percentag
area
miss
dorsum
palm
hand
calcul
wash
show
wide
variat
perform
total
area
miss
femal
perform
better
male
averag
area
miss
vs
nurs
better
doctor
vs
dorsum
hand
miss
palm
vs
area
miss
p
wash
follow
educ
subject
improv
perform
mean
reduct
area
miss
p
group
perform
significantli
better
age
sex
match
group
subject
educ
mean
area
miss
vs
p
addit
match
job
descript
alter
result
signific
differ
group
follow
educ
group
mean
area
miss
vs
comment
studi
demonstr
hand
wash
perform
hcw
poor
use
volum
gel
recommend
manufactur
improv
follow
educ
fluoresc
gel
uv
light
box
demonstr
effect
teach
method
howev
equival
effect
achiev
increas
amount
gel
use
illustr
case
vertebr
disciti
paravertebr
abcess
due
p
multocida
respond
conserv
treatment
ciprofloxacin
nonsurg
treatment
coamoxyclav
fail
case
report
year
old
man
establish
alcohol
liver
diseas
present
month
back
pain
intermitt
radiat
lumber
spine
left
foot
sphincter
disturb
occur
week
preced
admiss
develop
night
sweat
becam
bedbound
recal
scratch
cat
month
prior
admiss
requir
medic
attent
febril
tachycard
sever
pain
anal
sphincter
tone
rectal
examin
intact
straight
leg
rais
markedli
impair
bilater
reduc
pinprick
sensat
distribut
left
foot
reduc
reflex
left
leg
acut
inflammatori
respons
white
cell
count
creactiv
protein
g
dl
blood
cultur
grow
small
gram
neg
coccobacilli
identifi
pasteurella
multocida
api
test
biomerieux
franc
minimum
inhibitori
concentr
mic
amoxycillinclavulan
acid
ciprofloxacin
etest
method
magnet
reson
imag
mri
lumbar
spine
show
inflammatori
disciti
abscess
extend
posteriorli
imping
thecal
sac
mark
disc
space
narrow
treat
conserv
intraven
amoxycillinclavulan
acid
initi
deferves
four
day
treatment
becam
febril
associ
rise
crp
oral
ciprofloxacin
mg
twice
daili
prescrib
adjunct
treatment
temperatur
resolv
inflammatori
marker
normal
week
complet
resolut
abscess
mri
scan
mark
residu
destruct
vertebra
ciprofloxacin
prescrib
total
week
follow
default
followup
conclus
believ
second
document
case
paravertebr
abscess
due
p
multocida
first
ciprofloxacin
use
suggest
ciprofloxacin
place
treatment
deepseat
odhopaed
infect
pasteurella
speci
use
may
facilit
recoveri
without
requir
surgic
abscess
drainag
investig
creactiv
protein
crp
differenti
white
count
result
avail
rapidli
interest
result
rapid
investig
correl
bacteraemia
best
combin
rapidli
avail
result
order
detect
sever
commun
acquir
ill
address
studi
cohort
patient
admit
commun
clinic
suspect
infect
judg
take
blood
cultur
demograph
characterist
cohort
blood
cultur
isol
obtain
previous
describ
analyz
admiss
crp
result
well
full
blood
count
show
quantit
relationship
crp
concentr
admiss
lymphocyt
neutrophil
count
one
exclud
case
neutropenia
neutrophil
l
risk
bacteraemia
rise
continu
neutrophil
count
rise
crip
increas
cut
valu
evid
risk
also
increas
lymphocyt
count
declin
previous
describ
predict
commun
acquir
bacterem
ill
cohort
studi
crp
concentr
ad
littl
inform
provid
neutrophil
lymphocyt
count
data
assist
assess
bacteraemia
likelihood
patient
admit
commun
although
sever
report
emerg
metronidazol
resist
anaerob
laboratori
still
use
sensit
metronidazol
disc
preliminari
identif
anaerob
mix
cultur
metronidazol
also
wide
use
first
line
therapi
suspect
proven
case
anaerob
infect
describ
case
pelvic
abscess
caus
metronidazol
resist
bacteroid
fragili
result
treatment
failur
refer
lab
confirm
isol
b
fragili
pcrrestrict
fragment
length
polymorph
rflp
minimum
inhibitori
concentr
determin
mgl
nima
gene
associ
metronidazol
resist
identifi
strain
discuss
potenti
implic
identifi
anaerob
basi
metronidazol
sensit
also
need
perform
sensit
studi
anaerob
man
present
gp
increas
short
breath
orthopnoea
week
undergon
mitral
aortic
valv
replac
year
previous
rheumat
heart
diseas
take
longterm
steroid
therapi
prednisolon
mg
day
sarcoidosi
suffer
type
ii
diabet
mellitu
control
diet
alon
admiss
afebril
normal
white
cell
count
c
reactiv
protein
crp
transoesophag
echocardiogram
show
signific
paravalvular
leak
across
mitral
valv
schedul
second
mitral
valv
replac
convert
warfarin
intraven
heparin
day
admiss
develop
diarrhoea
pyrexia
becam
hypotens
crp
rose
gi
renal
function
deterior
repeat
echocardiogram
show
evid
infect
endocard
nonlactos
ferment
oxidas
neg
aerob
gramneg
rod
isol
four
set
blood
cultur
taken
day
apart
organ
appear
suscept
ampicillin
cephalosporin
ciprofloxacin
aminoglycosid
carbapenem
disc
diffus
test
could
identifi
biochem
routin
method
chest
xray
abdomin
xray
ultrasound
abdomen
show
focu
infect
peripher
intraven
cathet
site
presum
portal
entri
organ
patient
treat
ciprofloxacin
day
made
good
recoveri
mitral
valv
replac
carri
day
complet
cours
ciprofloxacin
current
well
month
post
surgeri
refer
laboratori
identifi
organ
acidovorax
speci
ga
chromatographi
cellular
fatti
acid
case
prove
pathogen
potenti
organ
clinic
set
grew
four
separ
blood
cultur
taken
day
patient
clinic
biochem
evid
sepsi
first
document
case
sepsi
due
acidovorax
diagnosi
suspect
involv
perform
urgent
cell
count
manual
time
consum
labori
sbp
lifethreaten
condit
requir
prompt
diagnosi
treatment
studi
suggest
use
urin
dipstick
suitabl
altern
cell
count
diagnos
sbf
therefor
evalu
use
leukocyt
esteras
le
dipstick
rapid
effect
bedsid
method
diagnos
sbp
method
ascit
fluid
sampl
acut
unwel
patient
chronic
liver
diseas
includ
studi
laboratori
cell
count
perform
use
fastread
count
chamber
follow
routin
cultur
sampl
cell
count
pmnml
also
cultur
blood
cultur
bottl
sampl
also
test
autom
aution
analys
use
uriflet
strip
sampl
test
presenc
le
blood
nitrat
read
spectrophotometr
result
one
hundr
thirti
ascit
fluid
sampl
patient
studi
seven
sampl
patient
satisfi
criterion
sbp
cell
count
sampl
also
posit
le
test
rang
leukocytesml
sensit
specif
test
respect
posit
predict
valu
low
test
excel
neg
predict
valu
detect
blood
nitrat
assist
diagnosi
sbr
patient
ascit
fluid
cultur
posit
howev
patient
manual
cell
count
diagnost
cultur
result
may
due
contamin
conclus
use
le
dipstick
ascit
fluid
sampl
rapid
reliabl
diagnost
method
exclud
sbp
use
laboratori
bedsid
major
ascit
fluid
sampl
cell
count
pmnml
use
le
dipstick
reduc
laboratori
workload
especi
outofhour
howev
le
posit
sampl
need
confirm
tradit
cell
count
microscopi
cultur
previou
studi
use
le
test
ascit
fluid
use
dipstick
differ
manufactur
produc
similar
neg
predict
result
period
end
februari
adult
sever
invas
group
streptococcu
ga
infect
admit
hospit
sheffield
uk
communityacquir
nonintraven
drug
user
one
patient
present
necrotis
fasciiti
hand
trivial
injuri
anoth
short
histori
dri
cough
malais
third
present
gp
swollen
knee
day
transient
sore
throat
latter
two
patient
develop
septic
shock
die
within
h
admiss
case
notabl
five
adult
seen
ga
bacteraemia
sheffield
first
month
review
public
health
inform
laboratori
data
suggest
might
part
widespread
problem
commun
respons
local
consult
communic
diseas
control
ccdc
trigger
alert
cascad
email
issu
sheffield
gener
practition
warn
vigil
manifest
sever
streptococc
sepsi
send
bacteri
throat
swab
patient
sore
throat
lower
usual
threshold
administ
antibiot
enhanc
awar
promptli
led
notic
rise
total
number
swab
receiv
howev
percentag
posit
ga
throat
swab
also
increas
sustain
period
analysi
data
outbreak
period
reveal
mark
increas
percentag
posit
compar
previou
year
isol
sever
diseas
show
high
proport
mucoid
strain
howev
serotyp
fail
identifi
predomin
type
amongst
strain
present
data
outbreak
discuss
role
laboratori
identifi
outbreak
ga
diseas
public
health
respons
highlight
need
close
liaison
microbiologist
infecti
diseas
public
health
manag
local
outbreak
infect
mean
crp
diagnosi
significantli
higher
primari
infect
group
ci
post
op
group
ci
differ
time
resolut
crp
follow
treatment
two
group
postop
patient
biopsi
cultur
postop
group
cultur
posit
blood
cultur
none
posit
patient
primari
infect
biopsi
cultur
cultur
posit
blood
cultur
posit
wider
varieti
organ
found
significantli
patient
primari
disciti
either
blood
cultur
biopsi
cultur
posit
vs
post
op
infect
pz
signific
differ
antibiot
use
length
time
antibiot
group
postop
patient
surgeri
surgeri
primari
infect
group
follow
death
primari
group
persist
neurolog
symptom
andor
pain
primari
group
vs
postop
group
conclus
postop
primari
disciti
similar
present
symptom
back
pain
rais
crp
case
primari
disciti
patient
like
premorbid
factor
grp
higher
primari
disciti
patient
like
posit
cultur
reflect
greater
system
upset
bacteraemia
wider
varieti
organ
found
primari
disciti
howev
treatment
outcom
vari
significantli
two
group
introduct
osteoarticular
tuberculosi
uncommon
repres
around
case
tuberculosi
case
involv
spine
peripher
joint
infect
less
common
tend
involv
singl
larg
joint
asymmetr
pattern
present
four
case
peripher
tubercul
arthriti
three
adult
one
child
present
servic
past
year
find
joint
involv
elbow
two
case
ankl
shoulder
case
swell
insidi
onset
pain
three
four
case
one
case
tender
effus
fourth
demonstr
synovi
thicken
without
pain
concomit
extraarticular
tuberculosi
two
case
asymptomat
pulmonari
one
case
pulmonari
periton
one
case
granulomat
myositi
anoth
site
although
two
patient
system
symptom
weight
loss
fever
sweat
mycobacterium
tuberculosi
cultur
joint
fluid
synovi
biopsi
three
four
case
fourth
bone
biopsi
show
nonspecif
inflamm
four
case
ethnic
background
tuberculosi
preval
higher
indigen
white
popul
three
histori
tuberculosi
contact
despit
one
case
diagnosi
delay
month
four
patient
receiv
standard
antitubercul
therapi
without
surgic
intervent
three
four
patient
made
full
recoveri
term
joint
function
one
patient
current
therapi
signific
improv
joint
symptom
mild
residu
limit
rang
movement
conclus
tuberculosi
peripher
joint
uncommon
consid
patient
subacut
joint
pain
andor
swell
particularli
epidemiolog
link
joint
symptom
may
initi
present
dissemin
tuberculosi
potenti
transmiss
other
delay
diagnosi
lead
progress
boni
destruct
may
irrevers
particularli
adult
earli
treatment
antitubercul
therapi
alon
usual
lead
complet
resolut
surgeri
requir
sever
joint
deform
london
inject
heroin
subcutan
skin
pop
intraven
social
unconnect
present
classic
symptom
dysadhria
diplopia
dysphagia
muscl
weak
examin
follow
clinic
sign
present
fever
ptosi
opthalmoplegia
dilat
poorli
respons
pupil
flaccid
limb
paralysi
rapid
onset
variabl
rang
day
patient
attend
e
dept
least
separ
occas
period
patient
present
respiratori
failur
requir
mechan
ventil
day
note
excess
saliv
endotrach
intub
one
patient
radiolog
featur
pneumonia
autonom
dysfunct
manifest
cardiovascular
instabl
arrhythmia
hypotens
also
promin
case
mous
bioassay
toxin
type
confirm
diagnosi
case
pcrassay
neuratoxin
gene
neg
abscess
pu
case
test
clostridium
botulinum
cultur
clinic
specimen
electrophysiolog
studi
show
characterist
abnorm
patient
reduc
motor
action
potenti
small
increment
increas
muscular
contract
transient
posit
tensilon
test
document
case
patient
receiv
botulinum
antitoxin
upon
clinic
diagnosi
without
advers
effect
surgic
drainag
skin
abscess
perform
case
abscess
identifi
remain
patient
receiv
antibiot
includ
metronidazol
benzyl
penicillin
hospit
stay
variabl
rang
day
excel
recoveri
minor
residu
neurolog
deficit
made
everi
case
wound
botul
inject
drug
user
describ
uk
sinc
increas
rapidli
botul
clinic
diagnosi
consid
skin
popper
present
occulobulbar
weak
andor
fulmin
respiratori
failur
skin
abscess
may
absent
nerv
conduct
studi
may
differenti
botul
caus
acuteonset
neuromuscular
weak
proper
report
clinic
diagnos
case
essenti
help
monitor
control
emerg
outbreak
male
inject
drug
user
idu
three
muscl
popper
age
rang
year
year
visual
disturb
blur
doubl
vision
earli
featur
present
follow
dysarthria
dysphagia
progress
weak
one
patient
complain
heavi
head
anoth
unabl
hold
head
respiratori
arrest
occur
two
patient
subsequ
consider
case
botul
three
patient
requir
mechan
ventil
tracheostomi
three
patient
admit
intens
care
durat
mechan
ventil
rang
day
median
day
four
patient
soft
tissu
abscess
clostridium
botulinum
type
organ
identifi
two
patient
excis
abscess
materi
fsml
mous
bioassay
perform
fsml
identifi
botulinum
toxin
type
serum
three
case
although
patient
waiv
botulinum
antitoxin
interv
admiss
administr
antitoxin
rang
day
conclus
wound
botul
consid
idu
present
neurolog
symptom
sign
earli
review
anaesthetist
advis
patient
suspect
wound
botul
yet
develop
respiratori
failur
initi
close
monitor
high
depend
unit
intens
care
unit
environ
outcom
wors
delay
administ
botulinum
antitoxin
longer
requir
mechan
ventil
intens
care
admiss
suspect
case
england
confirm
south
yorkshir
london
wound
botul
characteris
symmetr
afebril
descend
flaccid
paralysi
common
earli
symptom
includ
blur
vision
droop
eyelid
slur
speech
difficulti
swallow
breathless
muscl
weak
howev
patient
may
present
respiratori
failur
due
rapid
paralysi
respiratori
muscl
loss
sensat
conscious
lead
lock
syndrom
unrecognis
manag
includ
administr
specif
antitoxin
wound
debrid
antibiot
therapi
intens
respiratori
support
prognosi
good
diagnosi
recognis
treatment
commenc
earli
untreat
mortal
least
present
three
case
wound
botul
ivdu
manag
central
teach
hospit
june
juli
clostridium
botulinum
toxin
type
confirm
case
first
case
present
local
dgh
went
unrecognis
day
diagnosi
made
analysi
electromyographi
case
diagnos
treat
promptli
experienc
much
improv
outcom
yearold
intraven
drug
user
present
e
appar
drowsi
found
type
ii
respiratori
failur
respond
naloxon
flumazenil
respiratori
function
deterior
requir
intub
ventil
note
next
day
bilater
ptosi
despit
normal
pco
ventil
tensilon
test
perform
show
mark
improv
ptosi
suggest
myasthenia
gravi
effect
much
shorter
durat
usual
seen
myasthenia
atyp
syndrom
consid
lumbar
punctur
normal
found
small
lesion
buttock
skinpop
possibl
botul
rais
treat
presumpt
botul
follow
clinic
improv
taken
ventil
requir
reintub
hypercapnia
suffer
vf
arrest
follow
asystol
arrest
consequ
potassium
flux
due
suxamethonium
administr
set
botul
resuscit
success
went
recov
unev
case
one
sever
recent
case
botul
drugus
popul
scotland
diagnosi
consid
drug
user
present
neurolog
problem
respiratori
failur
tensilon
test
may
fals
posit
case
great
care
taken
induct
anaesthesia
due
potenti
lifethreaten
arrhythmia
associ
suxamethonium
administr
set
broad
spectrum
antibiot
meropenem
tazocin
increasingli
reli
upon
treat
infect
caus
gram
neg
bacteria
much
discuss
local
two
drug
prefer
howev
data
level
antibiot
resist
usag
lack
end
audit
undertaken
resist
meropenem
tazocin
amongst
gram
neg
rod
isol
blood
cultur
bed
teach
hospit
nh
trust
usag
meropenem
tazocin
ceftriaxon
cefuroxim
gentamicin
vancomycin
period
also
examin
inform
obtain
microbiolog
pharmaci
comput
record
posit
blood
cultur
grew
gram
neg
rod
studi
period
meropenem
resist
remain
steadi
initi
fall
overal
level
rang
tazocin
resist
rang
signific
variat
throughout
signific
trend
data
minor
chang
rang
speci
resist
two
antibiot
time
usag
vancomycin
tripl
meropenem
gentamicin
doubl
period
p
wherea
cefuroxim
usag
remain
steadi
ceftriaxon
usag
fell
p
around
tazocin
usag
initi
increas
suppli
shortag
late
began
rise
toward
previou
level
conclus
singl
nh
hospit
trust
despit
signific
increas
usag
meropenem
vancomycin
gentamicin
signific
increas
level
resist
meropenem
tazocin
among
gram
neg
rod
isol
blood
cultur
impli
concern
increas
resist
two
drug
unfound
trust
ought
affect
prescrib
polici
howev
continu
surveil
requir
local
nation
inform
regular
review
antibiot
prescrib
polici
inappropri
use
antibiot
widespread
lead
emerg
resist
organ
caus
unwant
advers
effect
place
extra
financi
cost
health
servic
attempt
improv
prescrib
habit
doctor
larg
unsuccess
studi
carri
beaumont
hospit
tertiari
referr
teach
hospit
dublin
four
consecut
week
current
antibiot
prescript
three
gener
surgic
ward
assess
clinic
microbiolog
team
prescript
deem
inappropri
conform
hospit
antibiot
guidelin
durat
antibiot
treatment
exceed
guidelin
dose
dosag
interv
incorrect
altern
agent
indic
avail
sensit
result
instanc
inappropri
treatment
recommend
chang
prescript
made
medic
chart
member
surgic
team
contact
advic
document
whether
advic
follow
treatment
felt
inappropri
prescript
studi
two
common
reason
treatment
deem
inappropri
prolong
administr
periop
prophylaxi
coadministr
metronidazol
coamoxiclav
case
recommend
chang
treatment
made
advis
chang
implement
tri
effect
improv
antibiot
prescrib
manner
timeintens
h
week
yield
moder
result
two
specif
area
inappropri
antibiot
use
identifi
intervent
target
plan
triclosan
wide
use
broad
spectrum
biocid
recommend
elimin
methicillinresist
aureu
mrsa
carriag
mrsa
isol
reduc
suscept
triclosan
describ
reduc
triclosan
suscept
shown
occur
overexpress
aminoacid
chang
fabl
studi
undertaken
determin
preval
reduc
triclosan
susceptibl
mrsa
isol
role
fabl
mutat
triclosan
resist
potenti
transfer
triclosan
resist
link
antimicrobi
resist
suscept
aureu
isol
triclosan
varieti
antimicrobi
compound
determin
agar
dilut
disc
diffus
method
direct
nucleotid
sequenc
pcr
amplim
use
detect
chang
fabl
cure
resist
attempt
growth
elev
temperatur
conjug
transfer
resist
carri
mix
cultur
recipi
number
isol
show
reduc
triclosan
suscept
found
low
despit
widespread
use
triclosan
evid
found
concomit
antimicrobi
resist
associ
reduc
triclosan
suscept
includ
mupirocin
resist
although
major
isol
examin
aminoacid
chang
fabl
essenti
reduc
suscept
triclosan
suggest
mechan
may
involv
attempt
transfer
cure
triclosan
resist
unsuccess
suggest
plasmid
involv
resist
isol
sourc
thought
unscreen
blood
pakistan
condit
deterior
next
day
develop
liver
failur
ascit
coagulopathi
liver
transplant
consid
thought
inappropri
given
age
signific
cardiovascular
comorbid
altern
therefor
sought
commenc
combin
adefovir
mg
daili
lamivudin
mg
daili
hbv
dna
level
quantifi
weekli
pcr
taqman
treatment
rapid
tan
hbv
viral
load
seen
copiesml
admiss
copiesml
discharg
correspond
signific
clinic
improv
discharg
home
day
admiss
length
stay
decreas
mean
day
day
day
mean
bed
occup
rose
timescal
modal
rate
decreas
overal
rate
noninfect
case
drop
infect
case
figur
larg
unchang
respect
modal
hivrel
admiss
conclus
comparison
three
studi
three
decad
illustr
chang
natur
admiss
three
decad
region
infect
unit
time
see
rel
infect
case
confirm
impress
clinician
admiss
increas
gener
length
stay
decreas
bed
occup
increas
hiv
data
parallel
situat
elsewher
inpati
admiss
reduc
mortal
greatli
reduc
insight
gain
put
practic
use
plan
futur
servic
improv
qualiti
effici
unit
although
receiv
mrsa
sampl
almost
everi
gp
belfast
area
surpris
greatest
concentr
isol
came
number
larg
multidoctor
multipractic
health
centr
mrsa
posit
practic
gener
staphylococcu
aureu
isol
rang
mean
signific
chang
monthli
total
mrsa
time
period
conclus
map
softwar
use
mean
visual
present
microbi
epidemiolog
data
antibiot
resist
inform
public
health
debat
direct
educ
surveil
activ
nonhospit
set
microsoft
mappoint
limit
coverag
northern
ireland
great
britain
postcod
may
slight
inaccuraci
abil
accur
map
mrsa
limit
incomplet
patient
postcod
data
patient
studi
similarli
knowledg
hospit
contact
recent
antibiot
use
might
facilit
pertin
analysi
antibiot
resist
commun
would
recommend
techniqu
pathogen
clostridium
difficil
resist
phenotyp
penicillin
resist
pneumococci
extend
spectrum
blactamas
pauciti
epidemiolog
data
nonhospit
set
penicilliosi
marneffei
life
threaten
invas
fungal
infect
caus
penicillu
marneffei
report
predominantli
southeast
asia
southern
china
though
penicilliosi
discov
china
earli
diseas
associ
hiv
infect
confirm
late
china
sinc
case
dissemin
penicilliosi
marneffei
aid
report
china
case
includ
male
male
age
rang
patient
acquir
hiv
infect
due
heterosexu
contact
andor
inject
drug
use
fever
cough
anemia
seen
case
rash
lymphadenopathi
found
case
splenomegali
hepatomegali
present
case
respect
oral
candidiasi
commonest
complic
associ
coinfect
p
marneffei
yield
cultur
blood
bone
marrow
secret
skin
lesion
pleural
fluid
pericardi
fluid
fungu
also
found
smear
bone
marrow
biopsi
lymph
node
skin
lesion
case
receiv
antifung
therapi
use
amphotericin
b
andor
one
azol
fluconazol
itraconazol
interestingli
fluconazol
alon
made
two
patient
condit
obvious
reliev
though
p
marneffei
usual
resist
agent
case
cure
improv
die
lost
conclus
unlik
southeast
asia
penicilliosi
marneffei
remain
rare
opportunist
infect
associ
hiv
infect
frequent
seen
hiv
neg
individu
china
diseas
primarili
found
guano
provinc
southern
china
howev
diseas
spread
part
china
includ
beij
guangdong
yunnan
sichuan
fever
cough
anemia
rash
lymphadenopathi
hepatosplenomegali
common
manifest
p
marneffei
hiv
coinfect
penicilliosi
fatal
opportunist
infect
aid
patient
new
case
policeman
resid
guangxi
provinc
year
present
counti
hospit
histori
high
fever
cough
provision
diagnosi
pulmonari
tuberculosi
made
receiv
antituberculosi
chemotherapi
month
without
clinic
improv
follow
admiss
west
china
hospit
blood
bone
marrow
cultur
well
bronchoscop
biopsi
posit
p
marneffei
confirmatori
serolog
test
hiv
posit
combin
therapi
amphotericin
b
itraconazol
institut
patient
made
good
clinic
respons
endobronchi
involv
caus
emerg
fungal
microorgan
rare
describ
previous
clinician
need
awar
hiv
posit
patient
histori
resid
travel
southern
china
clinic
present
suggest
tuberculosi
respond
poorli
antituberculosi
treatment
may
penicilliosi
marneffei
infect
object
million
peopl
worldwid
known
infect
filari
nematod
onchocerca
volvulu
caus
agent
onchooerciasi
usual
method
diagnosi
acquisit
skin
snip
microscopi
presenc
typic
microfilaria
mf
invas
patient
lack
sensit
especi
earli
infect
sensit
specif
onchocerciasi
elisa
base
recombin
antigen
previous
develop
test
known
mf
posit
patient
research
level
studi
use
antigen
set
valid
onchocerciasi
assay
use
diagnost
tertiari
referr
laboratori
materi
method
antigen
produc
incorpor
indirect
noncompetit
elisa
test
sera
previous
untreat
mf
posit
individu
cameroon
guatemla
assay
also
test
definit
probabl
onchocerciasi
patient
hospit
determin
specif
assay
test
sera
patient
loa
loa
wuchereria
bancrofti
mansonella
perstan
well
sera
patient
intestin
nematod
helminth
infect
sera
travel
endem
evid
helminth
infect
use
control
addit
step
perform
serial
sera
patient
determin
effect
perform
assay
sera
also
underw
test
current
inhous
brugia
pahangi
antigen
base
filaria
assay
direct
comparison
assay
could
perform
result
sera
mf
posit
patient
cameroon
sera
mf
posit
patient
guatemala
test
posit
assay
patient
onchocerciasi
diagnos
hospit
test
posit
assay
specif
assay
calcul
patient
onchocerciasi
neg
patient
test
posit
sensit
hous
filaria
assay
sera
known
onchocerciasi
patient
cameroon
guatemala
hospit
respect
addit
step
improv
perform
characterist
assay
discuss
develop
sensit
specif
onchocerciasi
assay
base
recombin
antigen
excel
result
test
sera
previous
untreat
patient
onchocerciasi
patient
diagnos
hospit
receiv
ivermectin
treatment
prior
serolog
test
result
show
improv
current
filaria
elisa
high
sensit
diagnosi
onchocerciasi
high
fals
posit
rate
especi
patient
infect
stronygloid
stercorali
epidemiolog
investig
perform
analyz
profil
resist
communityassoci
staphylococcu
aureu
antibiot
assess
spread
genotyp
communityassoci
methicillinresist
aureu
camrsa
aureu
strain
isol
nasal
swab
healthi
volunt
januari
decemb
seoul
korea
suscept
antistaphylococc
drug
studi
antibiogram
method
evolutionari
relationship
camrsa
hospitalacquir
mrsa
hamrsa
elucid
pulsedfield
gel
electrophoresi
pfge
analysi
smal
macrofrag
well
staphylococc
cassett
chromosom
mec
type
pcr
analysi
resist
rate
isol
penicillin
erythromycin
gentamicin
tetracyclin
cephalothin
oxacillin
mrsa
isol
respect
also
resist
rate
clindamycin
ciprofloxacin
sulfamethoxazoletrimethoprim
respect
howev
none
isol
resist
rifampin
nitrofurantoin
teicoplanin
vancomycin
pcr
analysi
exhibit
mrsa
isol
contain
maca
specif
gene
mani
contain
sequenc
contrast
result
similar
studi
pfge
reveal
cmrsa
isol
share
common
puls
field
type
observ
hamrsa
infect
korea
harbor
sever
variant
staphylococc
cassett
chromosom
mec
type
ii
iv
suggest
strain
close
link
previous
known
isol
year
old
femal
woman
south
african
origin
describ
origin
present
fever
weight
loss
anaemia
vomit
imag
studi
reveal
mark
intraabdomin
lymphadenopathi
pancreat
cyst
peripancreat
inflamm
hypodens
lesion
liver
spleen
bowel
wall
thicken
found
posit
count
l
hiv
vil
log
copiesml
lymph
node
biopsi
possibl
technic
reason
empir
antitubercul
chemotherapi
commenc
suspect
intraabdomin
tuberculosi
mycobacterium
tuberculosi
subsequ
isol
urin
sampl
stormi
cours
includ
persist
upper
small
bowel
obstruct
manag
conserv
pancreat
sever
nutrit
impair
secondari
fungal
periton
eventu
improv
discharg
hospit
admiss
howev
week
later
repres
mark
abdomin
distens
paracentesi
reveal
milki
white
fluid
consist
chylou
ascit
recurr
despit
regular
drainag
therapeut
intervent
chylou
ascit
unusu
condit
commonli
associ
intraabdomin
malign
surgic
intervent
variou
infect
includ
tuberculosi
occasion
report
caus
report
chylou
ascit
patient
aid
rare
case
relat
lymphoma
mac
diseas
ks
tuberculosi
describ
prognosi
appear
poor
optim
manag
unclear
present
potenti
manag
option
includ
medium
chain
triglycerid
diet
synthet
somatostatin
analogu
octreotid
discuss
present
patient
respons
measur
also
describ
major
medic
student
undertak
period
elect
studi
abroad
signific
proport
student
choos
elect
develop
countri
preval
hiv
consider
higher
uk
often
exposur
prone
special
trauma
surgeri
obstetr
gynaecolog
aim
assess
current
inform
avail
manchest
univers
medic
student
regard
elect
focuss
particularli
hiv
postexposur
prophylaxi
pep
method
questionnair
distribut
medic
student
attend
preelect
seminar
north
manchest
gener
hospit
nmgh
year
period
juli
juli
complet
immedi
lectur
student
took
suppli
pep
elect
ask
complet
questionnair
return
pep
avail
student
attend
seminar
plan
elect
countri
hiv
preval
result
student
complet
pretravel
student
posttravel
questionnair
major
plan
elect
subsaharan
africa
group
chosen
exposur
prone
special
student
report
receiv
advic
countri
special
choos
health
advic
preelect
obtain
varieti
sourc
commonli
gener
practition
follow
preelect
seminar
nnigh
awar
risk
catch
hiv
needlestick
risk
mucos
splash
injuri
understood
greater
risk
reduct
pep
taken
post
travel
respond
one
student
receiv
needlestick
injuri
hiv
posit
patient
two
student
mucos
splash
injuri
hiv
neg
patient
student
receiv
needlestick
injuri
took
pep
conclus
questionnair
return
student
manchest
medic
school
exposur
incid
last
year
true
figur
like
much
higher
medic
school
duti
care
ensur
student
awar
potenti
health
risk
elect
recommend
medic
school
adopt
polici
educ
student
risk
catch
hiv
ensur
pep
avail
individu
identifi
three
exclud
analysi
two
hcv
antibodi
seroconvers
outsid
year
one
newli
diagnos
follow
data
week
homosexu
hivinfect
male
diagnosi
acut
hcv
age
mean
year
durat
hiv
infect
mean
year
count
mean
cellsml
haart
hcv
genotyp
type
type
type
untyp
present
investig
abnorm
lft
perform
part
routin
hiv
care
symptom
outcom
treat
acut
phase
spontan
lost
detect
hcv
rna
period
follow
patient
treat
acut
phase
complet
treatment
respond
end
treatment
relaps
conclus
ongo
transmiss
hcv
among
hivinfect
homosexu
men
case
acut
hcv
identifi
routin
monitor
lft
hiv
care
patient
clear
hcv
rna
spontan
among
treat
virolog
respons
poor
rct
longer
treatment
combin
therapi
need
